Gland Pharma Ltd

Gland Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gland Pharma Ltd

₹ 1,668 -0.65%
20 Jan 4:01 p.m.
glandpharma.com BSE: 543245 NSE: GLAND
About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Key Points

Revenue breakup
Gland Pharma is primarily a contract manufacturer of injectables, with B2B segment generating ~95% of revenues in FY22 [1]

Website BSE NSE
  • Market Cap ₹ 27,485 Cr.
  • Current Price ₹ 1,668
  • High / Low ₹ 2,221 / 1,586
  • Stock P/E 39.7
  • Book Value ₹ 533
  • Dividend Yield 1.20 %
  • ROCE 13.6 %
  • ROE 9.26 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Company has a low return on equity of 12.5% over last 3 years.
  • Dividend payout has been low at 14.2% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -6.19%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE 400 MidSmallCap Index BSE 250 LargeMidCap Index Nifty Total Market BSE 500 Nifty 500 Multicap 50:25:25

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
1,080 1,063 1,103 857 1,044 938 785 1,209 1,373 1,545 1,537 1,402 1,406
704 714 755 587 748 649 617 915 1,049 1,189 1,179 1,137 1,109
Operating Profit 377 349 348 270 297 290 168 294 324 356 359 264 297
OPM % 35% 33% 32% 32% 28% 31% 21% 24% 24% 23% 23% 19% 21%
51 46 65 74 66 62 -18 38 53 37 42 51 60
Interest 1 1 2 1 2 3 2 5 6 5 10 6 6
Depreciation 26 28 31 35 37 38 38 65 81 105 93 92 94
Profit before tax 401 366 380 308 324 311 111 261 290 283 298 218 257
Tax % 25% 25% 25% 26% 26% 25% 29% 26% 33% 32% 35% 34% 36%
302 273 286 229 241 232 79 194 194 192 192 144 164
EPS in Rs 18.39 16.62 17.40 13.92 14.65 14.08 4.78 11.79 11.78 11.65 11.68 8.73 9.93
Raw PDF
Upcoming result date: 3 February 2025

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
2,633 3,463 4,401 3,625 5,665 5,890
1,678 2,161 2,890 2,600 4,332 4,614
Operating Profit 955 1,302 1,510 1,025 1,333 1,276
OPM % 36% 38% 34% 28% 24% 22%
139 135 224 184 170 191
Interest 7 3 5 7 26 27
Depreciation 95 99 110 147 345 384
Profit before tax 993 1,335 1,619 1,055 1,133 1,056
Tax % 22% 25% 25% 26% 32%
773 997 1,212 781 772 692
EPS in Rs 49.88 60.94 73.75 47.42 46.90 41.99
Dividend Payout % 0% 0% 0% 0% 43%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 18%
TTM: 37%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: -8%
TTM: -6%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -22%
1 Year: -14%
Return on Equity
10 Years: %
5 Years: %
3 Years: 12%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 16 16 16 16 16 16
Reserves 3,631 5,887 7,141 7,942 8,707 8,772
5 5 5 4 372 327
435 588 671 814 1,515 1,752
Total Liabilities 4,086 6,496 7,834 8,778 10,611 10,867
968 954 1,502 1,571 3,947 4,021
CWIP 188 338 191 177 238 277
Investments 0 0 155 0 0 0
2,929 5,204 5,986 7,030 6,426 6,569
Total Assets 4,086 6,496 7,834 8,778 10,611 10,867

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
701 605 791 364 997
-761 -1,520 -999 1,211 -1,749
-7 1,238 35 15 -799
Net Cash Flow -67 323 -174 1,590 -1,552

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 83 71 89 88 100
Inventory Days 250 312 205 421 278
Days Payable 82 97 80 127 145
Cash Conversion Cycle 251 286 214 382 234
Working Capital Days 161 169 168 242 170
ROCE % 28% 25% 15% 14%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
58.00% 58.00% 57.87% 57.86% 57.86% 57.86% 57.86% 57.86% 57.86% 57.86% 51.83% 51.83%
11.30% 10.72% 9.41% 6.10% 4.67% 4.33% 2.80% 4.91% 4.05% 3.59% 6.88% 4.48%
11.66% 12.46% 17.36% 21.92% 23.13% 23.23% 23.38% 22.45% 24.17% 25.23% 32.83% 35.37%
19.05% 18.82% 15.35% 14.13% 14.35% 14.59% 15.97% 14.78% 13.93% 13.32% 8.46% 8.33%
No. of Shareholders 1,09,0971,09,0981,17,3391,27,8791,48,4691,50,5781,81,7471,61,6271,36,0211,22,3751,22,6651,22,358

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls